The US FDA's reevaluation of the safety of Acadia Pharmaceuticals Inc.'s Nuplazid (pimavanserin) should remind pharmaceutical executives of safety crises from years past – but also serve as a warning about what firms might face if Democrats succeed in taking back the House in the midterm elections this fall.
Nuplazid, a Parkinson's drug approved in 2016, was the subject of intense questions by Rep. Rosa DeLauro during an April...




